US2016215006A1PendingUtilityA1
Peptidomimetic inhibitors of psma
Individually held — no corporate assignee on recordPriority: Nov 12, 2010Filed: Apr 1, 2016Published: Jul 28, 2016
Est. expiryNov 12, 2030(~4.3 yrs left)· nominal 20-yr term from priority
C07F 9/2458A61K 51/0489C07F 9/2408C07F 13/005C07F 9/24G01N 2333/705A61K 31/664A61P 35/00G01N 33/57555G01N 33/5759G01N 33/57434
40
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compounds of the formulae, (I), wherein each variable is as defined herein are provided which are useful in (i) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable carrier, excipient, and/or diluent; (3) methods for inhibiting or treating prostrate cancer; and (4) methods for blocking or destabilizing neovasculature of a tumor.
Claims
exact text as granted — not AI-modified1 - 17 . (canceled)
18 . A compound that is
wherein n is selected from 1-200.
19 . A compound that is a pharmaceutically acceptable salt of
20 . (canceled)
21 . A method for detecting and/or identifying cells presenting PSMA comprising contacting a cell suspected of presenting PSMA with a compound of any one of claims 18 or 19 .
22 - 23 . (canceled)Join the waitlist — get patent alerts
Track US2016215006A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.